Trial reportPsychopharmacology2014
Adverse effects from antidepressant treatment: randomised controlled trial of 601 depressed individuals.
Trial report in Psychopharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 2 syntheses or guidelines pooled it, 66 citations in OpenAlex.
- Acupuncture combined with antidepressants for mild-to-moderate depressive disorders: a systematic review with meta-analysis and trial sequential analysis.Frontiers in neurology · 2025Pooled it
- Sirukumab: A Potential Treatment for Mood Disorders?Advances in therapy · 2017Pooled it
- Placebo-controlled three-armed pilot trial of Escitalopram or Nortriptyline for depressive symptoms in Parkinson's disease (ADepT-PD).Journal of neural transmission (Vienna, Austria : 1996) · 2026Trial
- Sex differences in depressive symptoms and tolerability after treatment with selective serotonin reuptake inhibitor antidepressants: Secondary analyses of the GENPOD trial.Journal of psychopharmacology (Oxford, England) · 2021Trial
- Dose increase of S-Adenosyl-Methionine and escitalopram in a randomized clinical trial for major depressive disorder.Journal of affective disorders · 2020Trial
- The clinical effectiveness of sertraline in primary care and the role of depression severity and duration (PANDA): a pragmatic, double-blind, placebo-controlled randomised trial.The lancet. Psychiatry · 2019Trial
- Article
- Patients Reported Adverse Effects of Antidepressants Among Depressive Disorder and Associated Risk Factors: A Multicenter Cross-Sectional Study.Depression and anxiety · 2026Article
- Development of erectile dysfunction in men treated for major depressive disorder with selective serotonin reuptake inhibitors: a systematic review.Archives of medical science : AMS · 2026Review
- Psychological Adverse Events and Associated Safety Profiles of Doxepin: A Pharmacovigilance Study Using VigiBase.Journal of Korean medical science · 2025Article
- The short-term effectiveness of antidepressants in a transdiagnostic sample and determinants of side effects and medication nonadherence: an observational study.Frontiers in psychiatry · 2025Article
- A novel probiotic formula, BLLL, ameliorates chronic stress-induced depression-like behaviors in mice by reducing neuroinflammation and increasing neurotrophic factors.Frontiers in pharmacology · 2024Article
- Reasons for Discontinuation or Change of Selective Serotonin Reuptake Inhibitors in Online Drug Reviews.JAMA network open · 2023Article
- Psychotherapy with Psilocybin for Depression: Systematic Review.Behavioral sciences (Basel, Switzerland) · 2023Review
- Considerations for Optimizing Warfighter Psychological Health with a Research-Based Flavonoid Approach: A Review.Nutrients · 2023Review
- Prevalence of constipation in patients undergoing chemotherapy and the effect of constipation on quality of life.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022Article
- Microbial Ecosystem Therapeutic-2 Intervention in People With Major Depressive Disorder and Generalized Anxiety Disorder: Phase 1, Open-Label Study.Interactive journal of medical research · 2022Article
- An Active Inference Approach to Dissecting Reasons for Nonadherence to Antidepressants.Biological psychiatry. Cognitive neuroscience and neuroimaging · 2021Article
- Detection of adverse drug events in e-prescribing and administrative health data: a validation study.BMC health services research · 2021Article
- Efficacy and brain mechanism of transcutaneous auricular vagus nerve stimulation for adolescents with mild to moderate depression: Study protocol for a randomized controlled trial.Pediatric investigation · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 3 countries.
Funding
Abstract
rationalePremature discontinuation of antidepressant drugs is a frequent clinical problem. Adverse effects are common, occur early on in treatment and are reported to be one of the main reasons for discontinuation of antidepressant treatment.
objectivesTo investigate the association between adverse effects occurring in the first 2 weeks of antidepressant treatment and discontinuation by 6 weeks as the outcome. To investigate the time profile of adverse effects induced by the selective serotonin reuptake inhibitor citalopram and the noradrenaline reuptake inhibitor reboxetine over 12 weeks of treatment.
methodsSix hundred and one depressed individuals were randomly allocated to either citalopram (20 mg daily) or reboxetine (4 mg twice daily). A modified version of the Toronto Side Effects Scale was used to measure 14 physical symptoms at baseline (medication free) and at 2, 6 and 12 weeks after randomisation.
resultsIndividuals randomised to reboxetine reported a greater number of adverse effects and were more likely to stop treatment than individuals receiving citalopram. Dizziness (OR 1.83; 95% CI 1.09, 3.09; p = 0.02) and the total number of adverse effects (OR 1.12; 95% CI 1.00, 1.25; p = 0.06) reported at 2 weeks were associated with discontinuation from overall antidepressant treatment by 6 weeks. Reports of adverse effects tended to reduce throughout the 12 weeks for both antidepressants.
conclusionsThe majority of adverse effects were not individually associated with discontinuation from antidepressant treatment. Reports of physical symptoms tended to reduce over time. The physical symptoms that did not reduce over time may represent symptoms of depression rather than antidepressant-induced adverse effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.